A Leading Company in Cell Therapy
Kadimastem (TASE:KDST) is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical needs.
Kadimastem (TASE: KDST) is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes.
Kadimastem’s visionary positioning and founding principles stem from the success of Professor Michel Revel’s previous invention of a blockbuster drug. The company is developing revolutionary regenerative therapies based on stem cells, moving away from the traditional curative therapies. The technology has been developed as a platform enabling the manufacturing of islet-like endocrine cells and glia restricted progenitors thus having potential applications for diabetes, and for neurodegenerative diseases such as ALS. The therapy is scalable and industrialized, to be commercialized as a stable “off the shelf” product and reduce the cost of treatments. For this, Kadimastem uses pluripotent cells (e.g. embryonic stem cells – hESCs) that have a unique ability to multiply infinitely without losing their “naivety” and to be able to become any cell type. The product is produced under GMP guidelines (similar to traditional therapeutics) in order to reach optimal medical results. The company developed a groundbreaking process to differentiate the cells in the lab, before their injection into the patient, unlike other technologies which transplant immature precursor cells. The company’s process markedly enhances the efficiency of the treatment.